SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 28.72 |
| Enterprise Value ($M) | 17.26 |
| Book Value ($M) | 15.38 |
| Book Value / Share | 2.81 |
| Price / Book | 1.87 |
| NCAV ($M) | -2.78 |
| NCAV / Share | -0.51 |
| Price / NCAV | -10.33 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.18 |
| Return on Assets (ROA) | -0.20 |
| Return on Equity (ROE) | -0.22 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.18 |
| Current Ratio | 1.18 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.48 |
| Assets | 20.64 |
| Liabilities | 5.26 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.43 |
| Operating Income | -10.72 |
| Net Income | -2.82 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -7.72 |
| Cash from Investing | 0.62 |
| Cash from Financing | 4.09 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Lui Darren | 14.50 | 18.64 | |
| 13G/A | Hudson Bay Capital Management LP | 3.05 | -90.03 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,998 | 24,623 | 12.18 | |
| 4,829 | 7,274 | 66.39 | |
| 7,563 | 30,867 | 24.50 | |
| 1,945 | 11,785 | 16.50 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALZN – Alzamend Neuro, Inc. | ANEB – Anebulo Pharmaceuticals, Inc. |
| ANIX – Anixa Biosciences, Inc. | APRE – Aprea Therapeutics, Inc. |
| APTO – Aptose Biosciences Inc. |
Financial data and stock pages provided by
Fintel.io